Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…Abstract Number: 1095 • ACR Convergence 2021
Improved Arthrocentesis and Fluid Yield of the Non-Effusive Knee Using Pneumatic Compression
Background/Purpose: Arthrocentesis is critical for diagnosis and therapy of joint disease; however, it is very difficult to obtain diagnostic fluid from an arthritic but clinically…Abstract Number: 1566 • ACR Convergence 2021
Hyperuricemia Is Associated with Vascular Endothelial Dysfunction – the Impact of Hyperuricemia on Flow Mediated and Nitroglycerin Mediated Dilatation of the Brachial Artery
Background/Purpose: Vascular endothelial cells line the entire circulatory system, these cells have very distinct and unique functions that are paramount to vascular biology. Hyperuricemia has…Abstract Number: 1571 • ACR Convergence 2021
Elevated Lactate, Procalcitonin Levels and SIRS (Systemic Inflammatory Response Syndrome) in a Subset of Patients with Gout
Background/Purpose: The intense inflammatory cascade of acute gouty inflammation makes it difficult to differentiate clinically between acute gouty inflammation and sepsis, particularly since they can…Abstract Number: 1574 • ACR Convergence 2021
Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography
Background/Purpose: The diagnostic gold standard for gout remains aspiration and identification of monosodium urate (MSU) crystals under polarised light microscopy. Joint aspiration is invasive and…Abstract Number: 1580 • ACR Convergence 2021
Whole Blood Gene Expression and eQTL Analysis Implicate GGT7 and FADS2 in Gout Pathogenesis
Background/Purpose: Gene expression studies of whole blood represent a powerful approach for understanding the pathogenesis of gout because differentially expressed transcripts may reflect the activation…Abstract Number: 1898 • ACR Convergence 2021
Risk of Major Adverse Cardiovascular Events in a Large Cohort of Patients with Acute Calcium Pyrophosphate Crystal Arthritis
Background/Purpose: Acute calcium pyrophosphate (CPP) crystal arthritis, also known as pseudogout, causes an acute inflammatory arthritis that shares clinical similarities with gout. We investigated the…Abstract Number: 0687 • ACR Convergence 2020
Musculoskeletal Manifestations in Patients with CD73 Deficiency
Background/Purpose: Arterial calcification due to deficiency of CD73 (ACDC) is a hereditary autosomal recessive ectopic mineralization syndrome caused by loss-of-function mutations in the 5'-nucleotidase Ecto…Abstract Number: 1573 • ACR Convergence 2020
Gout as an Immune-Related Adverse Event from Immune Checkpoint Inhibitors
Background/Purpose: Immune checkpoint inhibitors (ICI) are novel treatments approved for various tumours including melanoma, lung and kidney. By interacting with immunoregulatory molecules (programmed death-1 (PD-1),…Abstract Number: 0445 • ACR Convergence 2020
Dual-Energy CT in Gout Patients: Do All Color-Coded Lesions Actually Represent Monosodium Urate Crystals?
Background/Purpose: Dual-Energy CT (DECT) can acknowledge differences in tissue compositions and can color-code tissues with specific features including monosodium urate (MSU) crystals. However, when evaluating…Abstract Number: 0661 • ACR Convergence 2020
Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease
Background/Purpose: Gout and hyperuricemia (HU), serum urate (SU) > 6.8 mg/dL, often present in the context of chronic kidney disease. It has long been known…Abstract Number: 0670 • ACR Convergence 2020
Risk Factors for Pseudogout: An Electronic Medical Record Case-Control Study
Background/Purpose: Prior studies of calcium pyrophosphate crystal deposition disease (CPPD) epidemiology either focused on the entire spectrum of CPPD or identified patients with its acute…Abstract Number: 0676 • ACR Convergence 2020
Surveying Practicing Rheumatologists Regarding Gout Management and Barriers in Gout Care
Background/Purpose: The management of gout is heterogeneous across specialties and clinical settings. Gout has been demonstrated to be one of the most poorly managed conditions…Abstract Number: 0685 • ACR Convergence 2020
The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
Background/Purpose: Pegloticase is a mammalian recombinant uricase coupled to monomethoxy polyethylene glycol that is approved in the US for treatment of patients with chronic refractory…Abstract Number: 343 • 2019 ACR/ARP Annual Meeting
Emergency Department Length of Stay in Patients with Acute Gout
Background/Purpose: Emergency department (ED) visits for acute gout increased by approximately 20% between 2006 and 2014 in the United States. (1) Reducing ED length of stay…